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Abstract Lecithin:cholesteryl acyl transferase (LCAT), cho-
lesteryl ester transfer protein (CETP), phospholipid trans-
fer protein (PLTP), and lipoprotein lipases are involved in
high density lipoprotein (HDL) metabolism. We evaluated
the influence of insulin sensitivity and of the TaqIB CETP
gene polymorphism (B1B2) on plasma LCAT, CETP, and
 
PLTP activities (measured with exogenous substrates)
and their responses to hyperinsulinemia. Thirty-two non-
diabetic men without hyperlipidemia were divided in quar-
tiles of high (Q
 
1
 
) to low (Q
 
4
 
) insulin sensitivity. Plasma total
cholesterol, very low 
 
1
 
 low density lipoprotein cholesterol,
triglycerides, and apolipoprotein (apo) B were higher in Q
 
4
 
compared to Q
 
1
 
 (
 
P
 
 
 
,
 
 0.05 for all), whereas HDL choles-
terol and apoA-I were lowest in Q
 
4
 
 (
 
P
 
 
 
,
 
 0.05 for both).
Plasma LCAT activity was higher in Q
 
4
 
 than in Q
 
1
 
 (
 
P
 
 
 
,
 
 0.05)
and PLTP activity was higher in Q
 
4
 
 than in Q
 
2
 
 (
 
P
 
 
 
,
 
 0.05).
Insulin sensitivity did not influence plasma CETP activity.
Postheparin plasma lipoprotein lipase activity was highest
and hepatic lipase activity was lowest in Q
 
1
 
. Insulin infusion
decreased PLTP activity (
 
P
 
 
 
,
 
 0.05), irrespective of the de-
gree of insulin sensitivity. The CETP genotype exerted no
consistent effects on baseline plasma lipoproteins and
LCAT, CETP, and PLTP activities. The decrease in plasma
PLTP activity after insulin was larger in B1B1 than in B2B2
homozygotes (
 
P
 
 
 
,
 
 0.05).  These data suggest that insulin
sensitivity influences plasma LCAT, PLTP, lipoprotein li-
pase, and hepatic lipase activities in men. As PLTP, LCAT,
and hepatic lipase may enhance reverse cholesterol trans-
port, it is tempting to speculate that high levels of these fac-
tors in association with insulin resistance could be involved
in an antiatherogenic mechanism. A possible relationship
between the CETP genotype and PLTP lowering by insulin
warrants further study.
 
—Riemens, S. C., A. Van Tol, B. K.
Stulp, and R. P. F. Dullaart. 
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The negative relationship between the level of high
density lipoprotein (HDL) cholesterol and the risk of car-
diovascular disease is commonly explained by the crucial
role of HDL in reverse cholesterol transport (1–4). By this
process cholesterol from peripheral cells is taken up by
HDL and transported to the liver where it is metabolized
and excreted in the bile (2–4).
Several plasma proteins are involved in HDL metabo-
lism and remodeling. Phospholipid transfer protein
(PLTP) facilitates the transfer and exchange of phospho-
lipids between lipoproteins (2, 5, 6). This lipid transfer
has the ability to convert small-sized HDL (HDL
 
3
 
) in
smaller and larger particles (7, 8). During this process
pre
 
b
 
-HDL particles originate that can act as initial accep-
tors of free cholesterol from cell surfaces (2, 6, 9). Subse-
quently, free cholesterol is esterified within the HDL frac-
tion by lecithin:cholesterol acyl transferase (LCAT) (10).
Cholesteryl ester transfer protein (CETP) has the ability
 
Abbreviations: apo, apolipoprotein; BMI, body mass index; CETP,
cholesteryl ester transfer protein; FFA, free fatty acids; HL, hepatic li-
pase; HDL, high density lipoproteins; LCAT, lecithin:cholesterol acyl-
transferase; LDL, low density lipoproteins; LPL, lipoprotein lipase;
PCR, polymerase chain reaction; PLTP, phospholipid transfer protein;
VLDL, very low density lipoproteins; Q, quartile.
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to transfer cholesteryl ester from HDL towards very low
and low density lipoproteins (VLDL 
 
1
 
 LDL) (2, 3, 10, 11).
In addition, HDL metabolism is governed by lipoprotein
lipase (LPL) and hepatic lipase (HL) in such a way that
LPL-mediated hydrolysis of triglyceride-rich lipoproteins
enhances the incorporation of lipoprotein surface constit-
uents in HDL (10, 12) and that HL stimulates HDL tri-
glyceride hydrolysis (12) and pre
 
b
 
-HDL generation (13).
A low level of HDL cholesterol and high plasma triglyc-
erides are prominent features of the insulin resistance syn-
drome (14). Insulin resistance in non-diabetic and Type 2
diabetic subjects is associated with a tendency for lower
LPL activity and higher HL activity in post-heparin
plasma, alterations which may contribute to a low HDL
cholesterol (15–17). Little is known about the effect of
insulin resistance on the plasma activity levels of PLTP,
CETP, and LCAT and their possible responses to insulin
in non-diabetic individuals. Plasma CETP activity is higher
in obese than in lean subjects (18, 19). Moreover, a posi-
tive correlation between body mass index (BMI), the
waist/hip ratio, and plasma PLTP activity has been found
(19), whereas plasma LCAT activity is not related to obe-
sity (19). Acute endogenous and exogenous hyperin-
sulinemia lowers plasma PLTP activity (20, 21), and this
effect is diminished in obese Type 2 diabetic patients (21).
Equivocal effects of insulin on plasma CETP activity have
been reported, including a lack of effect in both healthy
and Type 2 diabetic subjects (20, 21), a more pronounced
decrease in Type 2 diabetic compared to control subjects
(22) and vice versa (23).
HDL cholesterol metabolism is also under genetic con-
trol (24). Among other factors, the B1B2 polymorphism
of intron 1 of the CETP gene (presence or absence of a
TaqIB restriction site) was found to be a determinant of
HDL cholesterol concentration in some (25–27), but not
in all studies (28, 29). Interestingly, the CETP gene poly-
morphism may be implicated in atherosclerosis develop-
ment (27, 29).
In the present study, the associations between insulin
resistance and lipoprotein lipases as well as plasma PLTP,
LCAT, and CETP activities and their responses to acute hy-
perinsulinemia were evaluated in men without diabetes
mellitus. The TaqIB CETP genotype was documented to
preliminary assess its effect on the possible LCAT and
lipid transfer protein responses to insulin.
SUBJECTS AND METHODS
 
Subjects
 
The study was approved by the local medical ethics committee
and all participants provided written informed consent. Only
non-smoking men participated to avoid effects of smoking and of
the menstrual cycle on lipid levels (30, 31). Maximal alcohol al-
lowance was 2 beverages per day. None of the participants had a
fasting plasma total cholesterol 
 
.
 
6.5 mmol/l and/or triglycer-
ides 
 
.
 
2.3 mmol/l on screening, clinically manifest cardiovascu-
lar disease, hypertension (defined as systolic blood pressure
 
>
 
160 mmHg and/or diastolic blood pressure 
 
>
 
95 mmHg, or a
family history of hyperlipidemia. None of the subjects used any
 
medication. The thyreotropin level, liver function tests, and the
serum creatinine level were within the normal range. Diabetes
was excluded by a 75 gram oral glucose tolerance test with a fast-
ing venous blood glucose level of 6.1 mmol/l and a 2 h postglu-
cose level of 10.0 mmol/l as cut-off values (32). Body mass index
(BMI) was calculated as weight divided by height squared, and se-
vere obesity, defined as a BMI 
 
.
 
30 kg/m
 
2
 
, was an exclusion crite-
rion. The waist/hip ratio was measured as the ratio of the small-
est circumference between rib cage and iliac crest and the largest
circumference between waist and thigh (33). The participants
did not change their dietary habits at least 2 weeks prior to the
study and they did not consume alcohol on the day before the study.
They were fasting from 20.00 h onwards. On the study day they
remained supine after 8.00 h. One hand vein was cannulated and
the intravenous catheter was kept patent with a NaCl drip (154
mmol/l, 30 ml/h). This hand was placed in a thermoregulated
box with an ambient temperature of 55
 
8
 
C in order to obtain arte-
rialized venous blood. A forearm vein of the contralateral arm
was cannulated for administration of dextrose and insulin. Base-
line blood samples were taken after 1 h of rest. A euglycemic
clamp was then started with insulin administered at a rate of 30
mU/kg/h during 3 h. An insulin bolus of 5 mU/kg was given di-
rectly before the start of the clamp. Blood glucose was measured
at 5–10-min intervals and its target level during the clamp was ap-
proximately 0.4 mmol/l below the fasting level. A variable dex-
trose infusion (20% w/w), to which KCl (10 mmol per 500 ml of
dextrose) was added, was infused to maintain the blood glucose
level. A subsequent blood sample was taken at the end of the
clamp. The mean glucose infusion rate (M value in 
 
m
 
mol/kg/
min) during the third hour of the clamp was calculated as a mea-
sure of insulin sensitivity. Thus, the higher the M value, the
higher was the insulin sensitivity.
 
Laboratory measurements
 
Blood was collected into ethylene diaminetetracetic acid (1.5
mg/ml)-containing tubes and placed on ice immediately. Plasma
was obtained within 30 min by centrifugation at 3000 rpm for 15
min at 4
 
8
 
C. Plasma samples were frozen at 
 
2
 
70
 
8
 
C until analysis.
Lipids were assayed in whole plasma and in the HDL fraction
after precipitation of apolipoprotein (apo) B-containing lipopro-
teins with polyethylene glycol-6000 (34). VLDL 
 
1
 
 LDL lipids
were calculated as the difference between plasma and the HDL
lipids. Cholesterol and triglycerides were measured enzymati-
cally. ApoA-I and apoB were measured by immunoturbidimetry
(Boehringer Mannheim, Almere, The Netherlands, cat. no.
726478 and 726494, respectively). Plasma free fatty acids (FFA)
were determined enzymatically (Wako, Germany, cat. no. 994-
754-75409). Plasma LCAT activity was measured using excess ex-
ogenous substrate containing [
 
3
 
H]cholesterol as described (19,
35). The plasma LCAT activity levels vary linearly with the
amount of plasma used in the incubation. The plasma CETP ac-
tivity level was determined after removal of VLDL 
 
1
 
 LDL from
each sample, using an isotope assay that measures the transfer of
[1-
 
1
 
4C-oleate]-cholesteryl ester from labeled LDL to an excess
of unlabeled pooled normal HDL (19, 36). To inhibit LCAT,
dithiobis-2-nitrobenzoic acid was added to the incubation mix-
ture. CETP activity was calculated as the bidirectional transfer be-
tween labeled LDL and HDL. The LCAT and CETP activity levels
so measured correlate strongly with the plasma mass concentra-
tions of these proteins (37, 38). Plasma PLTP activity was deter-
mined using a liposome vesicles-HDL system according to a pre-
viously described procedure (19, 39). Plasma samples were
incubated with [
 
3
 
H]phosphatidylcholine-labeled liposomes and
an excess of pooled normal HDL, with subsequent precipitation
of the liposomes using a mixture of NaCl, MgCl
 
2
 
, and heparin at
final concentrations of 230 mmol/l, 92 mmol/l, and 200 U/ml,
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respectively. The plasma PLTP activity level is linearly correlated
with the amount of plasma added to the assay system. The
method is not influenced by the phospholipid transfer promo-
ting properties of CETP (39). Plasma LCAT, CETP, and PLTP ac-
tivity levels were related to the activities measured in human pool
plasma and are expressed in arbitrary units (AU, corresponding
to the percentages of the activities in the pool plasma). Plasma
for LPL and HL activities was obtained 20 min after intravenous
administration of heparin, 50 IU/kg. This test was performed
within 2 weeks before the glucose clamp. LPL and HL were as-
sayed as reported previously (40).
Blood glucose was analyzed with an APEC glucose analyzer
(APEC Inc., Danvers, MA). Plasma insulin was measured by ra-
dioimmunoassay. Thyreotropin was assayed by immunochemilu-
minescence. Serum creatinine and transaminases, 
 
g
 
-glutamyl-
transferase, and alkaline phosphatase were measured with a
SMA-C autoanalyzer (Technicon Instruments Inc., Tarrytown,
NY).
The B1B2 polymorphism of intron 1 of the CETP gene was an-
alyzed as described (29, 41). Peripheral blood was used for DNA
extraction. Erythrocytes were lysed by ammonium chloride treat-
ment. Phenol/chloroform extraction was performed to extract
genomic DNA from leukocytes. Polymerase chain reaction
(PCR) mixtures contained template DNA (500 ng), primers (50
pmol), deoxynucleotide triphosphates (200 
 
m
 
mol/l each), Taq
polymerase (2.5 U, Pharmacia Inc., Sweden), and Taq pol buffer
(5 
 
m
 
l, Pharmacia Inc., Sweden) in a total volume of 50 
 
m
 
l. PCR
was carried out using a Perkin-Elmer Gene Amp PCR system
2400 (Perkin-Elmer Inc., Foster City, CA). The primers encom-
passed a 535 base pair DNA fragment that contains a polymor-
phic site in intron 1 of the CETP gene (29). Thirty cycles of 30
sec at 94
 
8
 
C, 30 sec at 60
 
8
 
C, and 60 sec at 73
 
8
 
C were used, and ali-
quots of the PCR products (15 
 
m
 
l) were then digested with 8 U of
TaqIB (Pharmacia Inc., Sweden) for 2 h at 65
 
8
 
C. Restriction frag-
ments were analyzed by agarose gel electrophoresis, ethidium
bromide staining, and visualization on an ultraviolet transillumi-
nator. The B1 allele contains the TaqIB restriction site and is split
into 361 and 174 base pair products upon digestion. The B2 al-
lele is unaffected by TaqIB digestion.
 
Statistical analysis
 
Parameters are given as mean 
 
6
 
 SD unless stated otherwise.
Data were divided according to quartiles of the M value (insulin
sensitivity) and according to the CETP genotype. Between-group
differences in baseline parameters and in changes in parameters
were evaluated by Kruskal-Wallis analysis of variance or by the un-
paired Wilcoxon test. Within-group changes in parameters were
analyzed by the paired Wilcoxon test. Duncan’s method was
applied to correct for multiple comparisons. Multiple stepwise
regression analysis was performed to disclose which parameters
independently contributed to HDL cholesterol. A two-sided 
 
P
 
value 
 
,
 
0.05 was considered significant.
 
RESULTS
Thirty-two men participated in the study, of whom 24
had normal glucose tolerance and 8 were categorized as
having impaired glucose tolerance according to the newly
proposed WHO criteria (32). This number of participants
was chosen to be able to divide them into quartiles of insu-
lin sensitivity (
 
Table 1
 
). There were no differences in age
among the quartiles. BMI tended to be higher (
 
P
 
 
 
,
 
 0.10)
and the waist/hip ratio was significantly higher in the
quartile of subjects with the lowest insulin sensitivity (Q
 
4
 
)
compared to the quartile of subjects with the highest insu-
lin sensitivity (Q
 
1
 
). No differences in fasting blood glucose
were found among the quartiles, whereas plasma insulin
levels at baseline and at the end of the clamp were higher
in Q
 
4
 
 than in Q
 
1
 
. Mean alcohol consumption in the entire
group was 0.6 
 
6
 
 0.7 drinks per day. In the whole group,
the coefficient of variation of blood glucose, reflecting the
stability of the clamp was 6.1 
 
6
 
 2.4%.
Plasma total cholesterol, VLDL 
 
1
 
 LDL cholesterol,
plasma triglycerides, and apoB levels were higher in Q
 
4
 
than in Q
 
1
 
, whereas HDL cholesterol and apoA-I levels
were lower in Q
 
4
 
 compared to Q
 
1
 
 (
 
Table 2
 
). Baseline
plasma FFA were not significantly different among the
quartiles of insulin sensitivity, but at the end of the clamp
plasma FFA were higher in Q
 
4
 
 than in Q
 
1
 
 and Q
 
2
 
. 
 
Figure 1
 
shows that LPL activity was lower in Q
 
3
 
 than in Q
 
1
 
. In the
combined quartiles with the lowest insulin sensitivity, LPL
activity was lower than in the combined quartiles with the
highest insulin sensitivity (118 
 
6
 
 48 vs. 143 
 
6
 
 39 U/l, 
 
P
 
 
 
,
 
0.05). HL activity was higher in Q
 
2
 
, Q
 
3
 
, and Q
 
4
 
 than in Q
 
1
 
.
Baseline plasma LCAT activity was higher in Q
 
4
 
 than in
Q
 
1
 
. Baseline plasma PLTP activity was higher in Q
 
4
 
 than in
Q
 
2
 
 and the difference between Q
 
4
 
 and Q
 
1
 
 was close to sig-
nificance (
 
P
 
 
 
,
 
 0.07). In the combined quartiles with the
lowest insulin sensitivity, baseline plasma PLTP activity was
higher than in the combined quartiles with the highest
sensitivity (89 
 
6
 
 12 vs. 80 
 
6
 
 12 AU, respectively, 
 
P
 
 
 
,
 
 0.05).
In contrast, no effect of insulin sensitivity on baseline
 
TABLE 1. Clinical characteristics, fasting blood glucose, and plasma insulin according
to quartiles of insulin sensitivity (M value)
 
Variable
Q
 
1
 
(n 
 
5
 
 8)
Q
 
2
 
(n 
 
5
 
 8)
Q
 
3
 
(n 
 
5
 
 8)
Q4
(n 5 8)
M value (mmol/kg/min) 43.7 6 9.8
(32.7–62.1)
28.6 6 2.1
(26.3–31.4)
23.2 6 2.3
(19.1–26.1)
12.7 6 4.0
(7.9–18.9)
Age (years) 50 6 8 54 6 8 51 6 8 55 6 8
BMI (kg/m2) 23.6 6 2.6 25.3 6 4.0 25.9 6 3.1 26.1 6 1.8
Waist/hip ratio 0.88 6 0.06 0.94 6 0.07 0.94 6 0.06 0.95 6 0.06a
Fasting blood glucose (mmol/l) 4.7 6 0.4 4.8 6 0.7 4.7 6 0.4 4.6 6 0.4
Plasma insulin (mU/l)
Baseline 9.3 6 3.3 10.4 6 5.2 9.4 6 4.0 14.7 6 6.4a
End of clamp 26.9 6 5.2 32.6 6 9.5 35.6 6 7.2 39.8 6 13.3a
Data given as mean 6 SD and range. M value, insulin sensitivity index; BMI, body mass index.
a P , 0.05 from quartile with highest insulin sensitivity (Q1).
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plasma CETP activity was observed (Fig. 1). Multiple re-
gression analysis showed that HDL cholesterol was posi-
tively related to plasma LCAT activity (P 5 0.01) and neg-
atively to plasma triglycerides (P , 0.001), HL activity
(P , 0.01), and plasma CETP activity (P 5 0.05, multiple
r 5 0.74). In this model, no significant relationships of
HDL cholesterol with plasma PLTP activity (P 5 0.15) and
LPL activity (P 5 0.54) were present. As illustrated in Fig.
2, no significant changes in plasma LCAT and CETP activ-
ity were found in any of the quartiles of insulin sensitivity
after insulin infusion. Plasma PLTP activity, in contrast,
was decreased by insulin in all quartiles. There was no
effect of insulin sensitivity on the % decrement in PLTP
activity.
Eight subjects had B2B2, 13 had B1B2, and 11 had
B1B1 CETP genotype. The B2 allele frequency was 45%.
The CETP genotype distribution was in Hardy-Weinberg
equilibrium (x2df2 5 0.52, n.s.). There were no significant
differences in age, BMI, waist/hip ratio, M value, fasting
blood glucose, as well as in plasma insulin at baseline and
at the end of the clamp among the three CETP genotype
groups (data not shown). No effects of the CETP geno-
type on HDL cholesterol, plasma apoA-I levels, plasma
LCAT activity, and CETP activity were observed (data not
TABLE 2. Fasting plasma lipid parameters according to quartiles of insulin sensitivity (M value)
Variable
Q1
(n 5 8)
Q2
(n 5 8)
Q 3
(n 5 8)
Q4
(n 5 8)
Plasma total cholesterol (mmol/l) 4.42 6 0.53 4.78 6 0.68 4.84 6 0.53 5.06 6 0.75a
VLDL 1 LDL cholesterol (mmol/l) 3.02 6 0.49 3.59 6 0.85c 3.70 6 0.61 4.12 6 0.72b
HDL cholesterol (mmol/l) 1.40 6 0.32 1.19 6 0.21 1.14 6 0.15a 0.94 6 0.18b
Plasma triglycerides (mmol/l) 0.72 6 0.17 0.96 6 0.38 0.85 6 0.20c 1.45 6 0.51b
Plasma FFA (mmol/l)
Baseline 489 6 48 481 6 245 510 6 233 607 6 351
End of clamp 41 6 17 36 6 28c 95 6 57 132 6 85a
Apolipoprotein A-I (g/l) 1.35 6 0.18 1.19 6 0.13 1.18 6 0.07a 1.12 6 0.13a
Apolipoprotein B (g/l) 0.68 6 0.11 0.80 6 0.15a 0.83 6 0.16a 0.88 6 0.18b
Data given as mean 6 SD.
a P < 0.05, b P , 0.01 from quartile with highest insulin sensitivity (Q1).
c P , 0.05 from quartile with lowest insulin sensitivity (Q4).
Fig. 1. Lipoprotein lipase (LPL, A) and he-
patic lipase (HL, B) activities in postheparin
plasma and baseline plasma lecithin:choles-
terol acyl transferase (LCAT, C), cholesteryl es-
ter transfer protein (CETP, D), phospholipid
transfer protein (PLTP, E) activities, according
to quartiles of insulin sensitivity (Q1 represents
the quartile with the highest insulin sensitiv-
ity). Bars denote mean and SEM. * P , 0.05
from Q1. ** P , 0.05 from Q4.
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shown). There was also no effect on HDL cholesterol,
when HDL was measured in unfrozen samples by sodium
phosphotungstate and MgCl2 precipitation. Plasma PLTP
activity was lower (P , 0.05) in B1B1 homozygotes (76 6
10 AU) than in B1B2 heterozygotes (91 6 13 AU), but the
difference between B1B1 and B2B2 homozygotes (84 6
12 AU) was not significant. Plasma LCAT activity did not
change during insulin infusion in any of the 3 CETP geno-
type groups. Plasma CETP activity fell slightly in B1B1 ho-
mozygotes (23.5 6 4.7%, P , 0.05), and the difference in
change with B2B2 homozygotes (0.6 6 5.1%) was signifi-
cant (P , 0.05). Plasma PLTP activity decreased in all
CETP genotype groups (P , 0.05 to P , 0.01). The de-
crease in PLTP activity was larger (P , 0.05) in B1B1
(28.7 6 7.7%) than in B2B2 homozygotes (24.8 6 4.4%).
The decrease in the B1B2 heterozygotes was 7.1 6 5.3%.
DISCUSSION
This study suggests that insulin sensitivity influences
LPL and HL activities in postheparin plasma, as well as
plasma LCAT and PLTP, but not CETP activity in non-
diabetic men. Thus, the well-documented higher plasma
triglyceride levels found in insulin-resistant individuals
(42, 43) do not only cluster with a lower plasma LPL activity
but also with higher plasma LCAT and PLTP activity levels.
The higher plasma LPL and lower HL activities in the
most insulin-sensitive individuals compared to more insu-
lin-resistant subjects extend recent observations in non-
diabetic men (17). In that study, insulin resistance was
indirectly assessed by documentation of fasting hyper-
insulinemia, and the difference in plasma HL activity
between subjects with low and high fasting serum insulin
levels was not significant (17). Another report has demon-
strated relationships between low plasma LPL activity,
high HL activity, and low HDL cholesterol, either as an
isolated abnormality or in conjunction with high plasma
triglycerides (16), although such associations have not al-
ways been observed (44). When multiple regression analy-
sis was performed in the present study, HDL cholesterol
was found to be negatively related to HL activity, whereas
there was no independent effect of LPL, in agreement
with our earlier data (45). This analysis furthermore
showed that HDL cholesterol was positively related to
plasma LCAT activity and negatively to plasma CETP activ-
ity, in keeping with the actions of these factors to generate
cholesteryl ester in the HDL fraction and to promote cho-
lesteryl ester transfer from HDL to triglyceride-rich lipo-
proteins (2, 10, 11). No independent effect of plasma
PLTP activity on the cholesterol concentration in the total
HDL fraction was observed. In vitro studies emphasized
the role of PLTP in HDL remodeling (6–9).
Novel observations of our study include the associations
of insulin sensitivity with plasma LCAT as well as PLTP
activity. The plasma LCAT and lipid transfer protein activ-
ity assays used in this study may be regarded as a measure
of their mass concentrations in plasma (37, 38). Using the
same assay, it was previously found that plasma LCAT ac-
tivity is positively correlated with plasma triglycerides (19),
and that plasma LCAT activity is higher in Type 2 diabetic
patients in conjunction with higher plasma triglyceride
levels (45). Although it is well established that insulin re-
sistance and plasma triglyceride levels are increased in
obesity (14, 46, 47), plasma LCAT activity is not related to
body mass index and waist/hip ratio (19). Therefore, adi-
pose tissue is unlikely to represent a primary site influenc-
ing the association between insulin resistance and high
plasma LCAT activity. Rather, it seems plausible that the
liver, which is considered to be an important source of
LCAT (48), is metabolically involved in the interrelation
between insulin resistance, high plasma triglycerides, and
LCAT activity. In support of this possibility, in vitro studies
have demonstrated that triglycerides and LCAT are co-
secreted by rat hepatocytes in culture when incubated with
FFA (49). A high level of plasma PLTP activity has been
documented in several situations associated with insulin
resistance, such as obesity (19, 21), smoking (30), and in
Fig. 2. Changes in plasma lecithin:cholesterol acyl transferase (LCAT, A), cholesteryl ester transfer protein (CETP, B), and phospholipid
transfer protein (PLTP, C) activities in response to insulin infusion, according to quartiles of insulin sensitivity (Q 1 represents the quartile
with the highest insulin sensitivity). Bars denote mean 6 SEM; * P , 0.05 from baseline.
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some (21, 45) but not all studies (50, 51) in Type 2 diabe-
tes mellitus. The present data suggest an association be-
tween insulin resistance and plasma PLTP activity in non-
diabetic, non-smoking men without severe obesity. High
plasma PLTP activity in obese Type 2 diabetic patients co-
incides with elevated plasma triglycerides and a dimin-
ished lowering of plasma PLTP, triglycerides, and FFA in
response to exogenous insulin (21). In the current study,
baseline plasma triglycerides as well as the plasma FFA lev-
els attained after insulin were highest in the most insulin-
resistant subjects, but no effect of the degree of insulin re-
sistance on the plasma PLTP response to insulin was
found. This observation suggests that a high basal plasma
PLTP level can be dissociated from a blunted decrease by
acute hyperinsulinemia in non-diabetic men. Adipose
tissue is likely to provide an important source of CETP in
human plasma (18, 19, 52, 53). Nonetheless, the plasma
level of CETP activity was not related to insulin sensitivity,
nor was there a clear response to insulin in the present
and our previous studies (20, 21). Other reports showed a
minor decrease in plasma CETP after insulin administra-
tion to non-diabetic patients (22, 23). Taken together, the
associations of insulin sensitivity with plasma LCAT and
PLTP, but not CETP activity and the lowering of PLTP, but
not LCAT and CETP by insulin provide support for the
notion that these plasma protein factors are affected dif-
ferently by the degree of insulin resistance and acute insu-
lin administration.
Several studies have shown that the B2B2 CETP geno-
type is associated with a higher HDL cholesterol and a
lower plasma CETP level (25–27). However, such associa-
tions have not been unequivocally reported (28, 29), and
appear to be modified by metabolic and environmental
factors (29, 41, 54). In the present study with a rather lim-
ited number of participants, no consistent effects of the
CETP genotype on plasma lipoproteins as well as on base-
line plasma CETP, PLTP, and LCAT activity levels were ob-
served. Our observation that the decrease in plasma PLTP
activity after insulin was smaller in B2B2 than in B1B1 ho-
mozygotes is of potential interest. In view of the possible
protective effect of the B2B2 genotype on atherosclerosis
(27, 29), and the considerable homology between cDNA
encoding for CETP and PLTP (55), this preliminary find-
ing warrants further evaluation.
Despite being implicated in low HDL cholesterol levels
(15–17, 56) (present study), in vitro studies suggest that a
high HL activity may promote reverse cholesterol trans-
port (13, 57). In accordance with an antiatherogenic func-
tion of HL, overexpression of HL in mice retards diet-in-
duced aortic cholesterol accumulation (58), and HL
deficiency is characterized by premature atherosclerosis
(59). Overexpression of LCAT in rabbits inhibits athero-
sclerosis development as well (60), but the effect of this
manipulation is strongly dependent on the species in-
volved (61). The plasma concentration of preb-HDL par-
ticles, which are considered to be antiatherogenic (9, 50),
is enhanced in human PLTP transgenic mice (62, 63).
Taken together, these experimental data support the hy-
pothesis that HL, LCAT, and PLTP activities may be in-
volved in a defense mechanism against atherosclerosis. Al-
though such evidence cannot be extrapolated to the
human situation, it is tempting to speculate that high levels
of HL, LCAT, and PLTP activities in association with insulin
resistance could imply an antiatherogenic phenomenon.
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